Acute lymphoblastic leukemia (ALL) is a bone marrow hematologic malignancy, which accounts for the most common type of cancer (25%) and disease related death in children.1 L-asparaginase (ASNase) was a breakthrough in the treatment of ALL with 93% of pediatric patients reaching complete remission after its administration.2 This therapeutic agent exerts its effect by catalyzing L-asparagine (Asn) hydrolysis to L-aspartic acid and ammonia. The gene discussed is ASPG; the disease is cancer.